Abstract:

Breast cancer is one of the most common and frequently⁃occurring malignant tumors in women all over the world，and it is one of the most important causes of female death. Related tumor markers and therapeu⁃ tic targets have become research hotspots. Postmenopausal hormone therapy（MHT）is the most effective approach to prevent and treat menopausal⁃related symptoms and chronic diseases. However，it may increase the risk of breast cancer，and its mechanism is still unclear. The 10⁃year follow⁃up results of the Women′s Health Initiative（WHI） study showed that the breast cancer risk of women in the estrogen alone treatment group was not increased，but decreased ，while the risk of breast cancer in the estrogen and progesterone combined treatment group was increased. Our previous studies have found that certain synthetic progesterone could significantly promote the prolif⁃ eration of human breast cancer cells with positive expression of PGRMC1. Recent studies have also found that blood PGRMC1 concentration was increased in breast cancer patients. If PGRMC1 can be developed into a breast cancer risk marker for routine screening before hormone therapy，it will be of great significance. Whether pGRMC1 can be used as a potential marker of patients susceptible to breast cancer during hormone therapy is reviewed in this paper.

Key words:

progesterone receptor membrane component 1, postmenopausal hormone therapy, breast cancer, estrogen, progesterone